Imukin (Recombinant Human Interferon Gamma 1b)

The molecule binds to interferon‑gamma receptors on immune cells, activating the JAK‑STAT pathway. This leads to increased expression of major histocompatibility complex molecules, enhanced macrophage antimicrobial activity, promotion of Th1 immune responses, and stimulation of osteoclast differentiation, which together address the underlying disease processes.

The specific dose and dosing schedule of Imukin are determined by the prescribing clinician based on the patient’s age, weight, disease severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing adverse effects.

The safety of Imukin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after careful consideration.

To place an order, submit an enquiry on the Imukin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Imukin (interferon‑gamma) differs from interferon‑alpha or beta products in its target receptor and immunologic effects. While interferon‑alpha primarily enhances antiviral defenses, interferon‑gamma specifically activates macrophages and promotes Th1‑type immunity, making it the preferred choice for conditions like chronic granulomatous disease and malignant osteopetrosis.

Imukin should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the lyophilized powder. Do not use the product if it has been exposed to temperatures outside this range.

Imukin is supplied as a lyophilized powder for injection. After reconstitution with the appropriate diluent, it is administered subcutaneously by a healthcare professional according to the prescribing information and the patient’s individualized dosing schedule.

Serious risks include hematologic abnormalities such as neutropenia or anemia, significant liver enzyme elevations, autoimmune reactions (e.g., lupus‑like syndrome), severe allergic responses including anaphylaxis, and pulmonary toxicity. Patients should be monitored regularly for these events.

Imukin is contraindicated in individuals with known hypersensitivity to interferon‑gamma or any excipients in the formulation. Caution is advised for patients with severe cardiac disease, active autoimmune disorders, or those receiving live vaccines, as these conditions may increase the risk of adverse outcomes.